Sign in

    Margarate Boeye

    Managing Director and Senior Equity Research Analyst at Raymond James

    Margarate Boeye is a Managing Director and Senior Equity Research Analyst at Raymond James, specializing in consumer and retail sectors. She covers major companies such as Walmart, Target, Dollar General, and Costco, and has been recognized for her accurate stock predictions and high success rates, with performance metrics often ranking in the top quartile among her peers on platforms like TipRanks. With a career in equity research that began in the early 2000s, Boeye previously held analyst roles at Morgan Keegan and other financial firms before joining Raymond James in 2012. She maintains active FINRA registrations, including Series 7, 63, 86, and 87 licenses, and has been frequently cited for her insightful industry commentary and client service excellence.

    Margarate Boeye's questions to SERA PROGNOSTICS (SERA) leadership

    Margarate Boeye's questions to SERA PROGNOSTICS (SERA) leadership • Q1 2025

    Question

    Margarate Boeye, on behalf of Andrew Cooper, inquired about the planned progression and investment size for strategic headcount in 2025 and asked for an update on the PRIME study's publication timeline.

    Answer

    President and CEO Evguenia Lindgardt stated that Sera Prognostics plans to expand its commercial team by 5 to 10 full-time employees, focusing on key target states, with potential for further expansion based on success. Regarding the PRIME study, Lindgardt confirmed the company has passed another milestone with its target journal but could not provide a precise publication date.

    Ask Fintool Equity Research AI

    Margarate Boeye's questions to SERA PROGNOSTICS (SERA) leadership • Q4 2024

    Question

    The analyst inquired about the specifics of the planned commercial investments, the required size of the commercial team, and the near-term pipeline, including the launch timeline and pricing for the Time to Birth assay.

    Answer

    The company is expanding its commercial team in waves, starting with regional account managers, medical liaisons, and revenue cycle staff in target states. For the pipeline, the Time to Birth assay and a Predictive Analytics product are targeted for launch in the second half of the year. The Time to Birth test will be priced around $150.

    Ask Fintool Equity Research AI

    Margarate Boeye's questions to Adaptive Biotechnologies (ADPT) leadership

    Margarate Boeye's questions to Adaptive Biotechnologies (ADPT) leadership • Q1 2025

    Question

    Maggie Boeye, on for Andrew Brackmann at William Blair, asked about the sources of operating leverage, future investment priorities, and the progress on the NeoGenomics partnership ahead of its pilot launch.

    Answer

    CFO Kyle Piskel identified leverage from higher lab volumes and field force productivity. Executive Susan Bobulsky outlined future investments in revenue cycle management, EMR technology, and data generation, with no near-term plans to expand the sales force. She confirmed the NeoGenomics partnership is on track, with key operational planning for the Phase I launch complete.

    Ask Fintool Equity Research AI

    Margarate Boeye's questions to AWH leadership

    Margarate Boeye's questions to AWH leadership • Q1 2024

    Question

    Inquired about the source of OvaWatch growth (new vs. existing accounts), early trends with the Longitudinal Monitoring launch, and details on the recent Anthem coverage update, including the timing for future contracts.

    Answer

    The company does not disclose the breakdown of growth by new versus existing accounts and stated it's too early for data on the new Longitudinal Monitoring launch, though they expect it to increase provider stickiness. The Anthem agreement currently covers California (6 million lives), with plans to expand to other regions systematically. A key development is that the credentialing is for the entire OvaSuite for the first time.

    Ask Fintool Equity Research AI